Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 11,586 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CHRONIC DISEASE Clear all
Completed Phase 1 Interventional

Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation

NCT01634217
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
iTreg
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Nov 10, 2026, 5:43 AM EST
Recruiting Phase 3 Interventional

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
INCA034176, Placebo, Corticosteroids
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 10, 2026, 5:43 AM EST
Active, not recruiting Phase 2 Interventional

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT04458610
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
Rituximab, Zanubrutinib
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 10, 2026, 5:43 AM EST
Recruiting Not applicable Interventional

Developing an Innovative Decision Support Tool for Pediatric Neuromuscular Scoliosis

NCT07167927
View directory record Official record
Conditions
Children With Medical Complexity (CMC), Multiple Chronic Conditions, Neuromuscular Scoliosis, Shared Decision Making, Decision Support Systems, Clinical, Decision Aids
Interventions
Decision support tool
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
8 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 10, 2026, 5:43 AM EST
Completed Early Phase 1 Interventional

Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease

NCT01308242
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sevelamer Carbonate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Nov 10, 2026, 5:43 AM EST
Terminated Early Phase 1 Interventional Results available

Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)

NCT00763035
View directory record Official record
Conditions
Coronary Artery Disease, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Angina
Interventions
Regadenoson, Dobutamine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Nov 10, 2026, 5:43 AM EST
Recruiting Not applicable Interventional

Paired Non-invasive VNS in Adolescent Cerebral Palsy Rehabilitation

NCT07394608
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Non-invasive taVNS
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 10, 2026, 5:43 AM EST
Terminated Not applicable Interventional Results available

Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access

NCT00448708
View directory record Official record
Conditions
Kidney Diseases, ESRD
Interventions
Vascular Wrap Paclitaxel-Eluting Mesh, Lifespan® ePTFE Vascular Graft
Device
Lead sponsor
Angiotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Fresno, California • Inglewood, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Nov 10, 2026, 5:43 AM EST
Completed Not applicable Interventional Results available

Effectiveness of Virtual Reality Gaming Therapy Versus CI Therapy for Upper Extremity Rehabilitation

NCT02631850
View directory record Official record
Conditions
Stroke, Hemiparesis
Interventions
Traditional CI Therapy, Gaming CI Therapy, Gaming CI Therapy with Additional Contact via Video Conference, Traditional Occupational Therapy/Physical Therapy
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Birmingham, Alabama • Columbia, Missouri • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Nov 10, 2026, 5:43 AM EST
Completed Phase 2 Interventional

Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease

NCT00345774
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
PRX-08066
Drug
Lead sponsor
Epix Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 79 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
19
States / cities
Anniston, Alabama • Phoenix, Arizona • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 29, 2008 · Synced Nov 10, 2026, 5:43 AM EST
Completed Not applicable Interventional Results available

Chronic Care Management/Patient Relationship Management Proof of Concept

NCT01182480
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Patient Relationship Management (PRM) Program
Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 76 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Nov 10, 2026, 5:43 AM EST
Completed Phase 2 Interventional

Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

NCT00004908
View directory record Official record
Conditions
Lymphoma
Interventions
cyclophosphamide, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2011 · Synced Nov 10, 2026, 5:43 AM EST
Completed Phase 1 Interventional

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

NCT00100997
View directory record Official record
Conditions
Leukemia
Interventions
tanespimycin
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Nov 10, 2026, 5:43 AM EST
Completed Not applicable Interventional

Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients

NCT00002062
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Spiramycin
Drug
Lead sponsor
Rhone-Poulenc Rorer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Horsham, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 10, 2026, 5:43 AM EST
Completed Not applicable Interventional Results available

Battlefield Auricular Acupressure (BAApress) Feasibility Study

NCT05939388
View directory record Official record
Conditions
Pain
Interventions
Auricular Acupressure Pads
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Nov 10, 2026, 5:43 AM EST
Completed Not applicable Interventional Results available

Effect of Adipokines in Hemodialysis Patients

NCT01301027
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Denver, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Nov 10, 2026, 5:43 AM EST
Completed Not applicable Interventional Results available

Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation

NCT00859586
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, Leukemia, Myelocytic, Chronic
Interventions
Miltenyi Magnetic cell sorter for CD3
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
8 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Nov 10, 2026, 5:43 AM EST
Recruiting Phase 1Phase 2 Interventional

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT03850574
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2, Chronic Myelomonocytic Leukemia
Interventions
Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion
Drug
Lead sponsor
Aptose Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Nov 10, 2026, 5:43 AM EST
Completed Not applicable Interventional

Effectiveness of Robotic Gait Training and Physical Therapy for Children and Youth With Cerebral Palsy

NCT02391324
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Lokomat (LOK), Gait focused physical therapy (fPT), LOK + fPT
Procedure
Lead sponsor
University of Alberta
Other
Eligibility
5 Years to 18 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 10, 2026, 5:43 AM EST
Completed Phase 3 Interventional Results available

A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines

NCT00232180
View directory record Official record
Conditions
Heart Failure
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
55 Years and older
Enrollment
2,743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
51
States / cities
Phoenix, Arizona • Loma Linda, California • Merced, California + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Nov 10, 2026, 5:43 AM EST
Completed No phase listed Observational

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

NCT05640180
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone (Kerendia, BAY94-8862), Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
17,847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Nov 10, 2026, 5:43 AM EST
Completed Phase 4 Interventional Results available

Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)

NCT01663103
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Aurora, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Nov 10, 2026, 5:43 AM EST
Completed Not applicable Interventional

Innovative Pulmonary Rehabilitation Telehealth Program for Improving COPD Patient Outcomes

NCT03489642
View directory record Official record
Conditions
COPD
Interventions
Telehealth Program
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Nov 10, 2026, 5:43 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

NCT03275740
View directory record Official record
Conditions
Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Nov 10, 2026, 5:43 AM EST